Six Unheard Proposals Revealed Here

Six proposals were not heard during the Coordination and Maintenance committee meeting.

The Coordination and Maintenance Committee Meeting was held March 9 – 10, 2021. The meeting began with discussion of the ICD-10-PCS topics. There were six proposals that were not discussed during the meeting which were therapeutic administration of drugs/substances.   This article will review the six proposals.    Remember that all comments for all procedure topics are due April 9, 2021.   The comments should be sent to ICDProcedureCodeRequest@cms.hhs.gov.

The first proposal was for the administration of Amivantamab which is used to treat epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer with Exon20 insertions.   The five-year survival rate is 8 percent with this type of cancer.   This drug is a fully human bispecific antibody that binds to the extracellular domains of the epidermal growth factor and mesenchymal epithelial transition (MET).   It is administered on a 28-day cycle on an outpatient basis.   Patients may need to be administered if admitted for other complications of the disease.  This drug has been designated as a breakthrough therapy and is currently working through clinical trials.

The second proposal is for the administration of Ciltacabtagene Autoleucel which is a B-cell maturation Antigen Directed CAR T-cell Therapy.   This drug treats relapsed/refractory multiple myeloma.   It takes approximately 57 days from registration to complete the initial round of therapy.   There is a PCS code for CAR T-cell therapy, but not specific to this type of therapy.

The third proposal is ENSPRYNG (satralizumab mwge) which is a humanized IgG2 monoclonal antibody which is used for treating Neuromyelitis Optica Spectrum Disorder (NMOSD).   Patients with this disorder relapsed 60% within one year and 90 percent within three years.   These patients required wheelchairs (50 percent) and could be functionally blind (62percent).  In the study, there was significant reduction in relapse.  This medication is given subcutaneously as an inpatient or outpatient.   After a loading dose, the medication is administered every four weeks.

The fourth proposal is administration of Trilaciclib which is a myelopreservation therapy.  The goal of this therapy is to mitigate chemotherapy induced myelosuppression in extensive non-small cell lung cancer patients.  Trilaciclib has been granted FDA breakthrough therapy status.   This medication is administered intravenously or via central line.  Patients are treated with four cycles of 21-day therapy.   The patient is given chemotherapy with Trilaciclib days 1 – 3 followed by 18 days treatment free.   One inpatient admission is expected, but the medication can be administered as an inpatient or outpatient.

The fifth proposal is administration of ZEPZELCA (lurbinectedin) which is a transcription inhibitor for patients with metastatic small cell lung carcinoma.   This is a second line option whose cancer has progressed while on traditional chemotherapy.  This medication has been approved by the Federal Drug Administration (FDA).   The schedule for this medication is every 21 days.   It can be administered on an inpatient or outpatient basis.

The last proposal is the transfusion of pathogen reduced cryoprecipitated fibrinogen complex (PRCFC) which is used to treat massive bleeding when patient is fibrinogen deficient.   This substance is not the same as the usual cryoprecipitate.   This substance has been approved by the FDA and was awarded breakthrough device designation.   PRCFC is treated by INTERCEPT Blood System which inactivates pathogens to reduce transfusion transmitted infections (TTI).   This product has a five-day at room temperature shelf-life.

These six drugs/products have requested New Technology Add-On Payment (NTAP) which provides additional reimbursement to the Medicare-Severity Diagnosis Related Group (MS-DRG).   In proposed rule for Inpatient Prospective Payment System (IPPS) FY22, a preliminary recommendation will be published.    These procedure codes are being considered for FY22 which begins Oct. 1, 2021.

Programming Note: Listen to Laurie Johnson report this story live today during Talk Ten Tuesdays, 10 a.m. Eastern.

 

 

Print Friendly, PDF & Email
Facebook
Twitter
LinkedIn

Laurie M. Johnson, MS, RHIA, FAHIMA, AHIMA Approved ICD-10-CM/PCS Trainer

Laurie Johnson is currently a senior healthcare consultant for Revenue Cycle Solutions, based in Pittsburgh, Pa. Laurie is an AHIMA-approved ICD-10-CM/PCS trainer. She has more than 35 years of experience in health information management and specializes in coding and related functions. She has been a featured speaker in over 40 conferences. Laurie is a member of the ICD10monitor editorial board and is a permanent panelist on Talk Ten Tuesdays

Related Stories

New Codes Proposed During Two-Day C&M Meeting

New Codes Proposed During Two-Day C&M Meeting

The Coordination and Maintenance (C&M) Committee meeting was held on Sept. 12 and 13. The meeting began with the procedure proposals, which were followed by

Read More

Leave a Reply

Please log in to your account to comment on this article.

Featured Webcasts

Leveraging the CERT: A New Coding and Billing Risk Assessment Plan

Leveraging the CERT: A New Coding and Billing Risk Assessment Plan

Frank Cohen shows you how to leverage the Comprehensive Error Rate Testing Program (CERT) to create your own internal coding and billing risk assessment plan, including granular identification of risk areas and prioritizing audit tasks and functions resulting in decreased claim submission errors, reduced risk of audit-related damages, and a smoother, more efficient reimbursement process from Medicare.

April 9, 2024
2024 Observation Services Billing: How to Get It Right

2024 Observation Services Billing: How to Get It Right

Dr. Ronald Hirsch presents an essential “A to Z” review of Observation, including proper use for Medicare, Medicare Advantage, and commercial payers. He addresses the correct use of Observation in medical patients and surgical patients, and how to deal with the billing of unnecessary Observation services, professional fee billing, and more.

March 21, 2024
Top-10 Compliance Risk Areas for Hospitals & Physicians in 2024: Get Ahead of Federal Audit Targets

Top-10 Compliance Risk Areas for Hospitals & Physicians in 2024: Get Ahead of Federal Audit Targets

Explore the top-10 federal audit targets for 2024 in our webcast, “Top-10 Compliance Risk Areas for Hospitals & Physicians in 2024: Get Ahead of Federal Audit Targets,” featuring Certified Compliance Officer Michael G. Calahan, PA, MBA. Gain insights and best practices to proactively address risks, enhance compliance, and ensure financial well-being for your healthcare facility or practice. Join us for a comprehensive guide to successfully navigating the federal audit landscape.

February 22, 2024
Mastering Healthcare Refunds: Navigating Compliance with Confidence

Mastering Healthcare Refunds: Navigating Compliance with Confidence

Join healthcare attorney David Glaser, as he debunks refund myths, clarifies compliance essentials, and empowers healthcare professionals to safeguard facility finances. Uncover the secrets behind when to refund and why it matters. Don’t miss this crucial insight into strategic refund management.

February 29, 2024
2024 ICD-10-CM/PCS Coding Clinic Update Webcast Series

2024 ICD-10-CM/PCS Coding Clinic Update Webcast Series

HIM coding expert, Kay Piper, RHIA, CDIP, CCS, reviews the guidance and updates coders and CDIs on important information in each of the AHA’s 2024 ICD-10-CM/PCS Quarterly Coding Clinics in easy-to-access on-demand webcasts, available shortly after each official publication.

April 15, 2024

Trending News

This Leap Year, celebrate success with a 29% discount one day ONLY! Use code LEAP24 on February 29th at checkout to unlock this offer! Click here to learn more.
It’s Heart Month! Use code HEART24 at checkout to receive 20% off your cardiology products. Click here to view our suite of Cardiology products!